TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report report published on Monday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.55 on Monday. The firm’s 50-day moving average price is $1.68 and its two-hundred day moving average price is $1.81. TherapeuticsMD has a 12-month low of $1.43 and a 12-month high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP lifted its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. 30.74% of the stock is owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.